Nicox and pSivida announced their entry into a collaboration agreement to explore the potential of combining Nicox's nitric oxide (NO)-donating compounds with pSivida's bioerodible sustained-release drug delivery system, to develop a sustained release drug to lower IOP in patients with glaucoma or ocular hypertension.
Nicox and pSivida will collaborate on the selection of NO-donating product candidates from Nicox's research portfolio to combine with pSivida's sustained-release drug technology. pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums by Nicox. The companies may then elect to proceed with further development, including more detailed nonclinical studies to generate preclinical data, and the evaluation of further compounds under the collaboration. Nicox would make additional payments for any incremental development activities for each implant formulation product candidate selected by Nicox to progress in development. New intellectual property from the collaboration relating to the drug-device combination will be jointly owned. Nicox and pSivida will negotiate a separate license agreement for any product candidate that the two companies wish to further develop and potentially commercialize as a result of this collaboration. Expected payments from Nicox associated with this agreement are not considered material to Nicox's financial statements at this time.
“We have strong preclinical data demonstrating the IOP lowering effect of our novel stand-alone NO donors, such as our lead NCX 667, and believe that their profile makes them product candidates for potential sustained release delivery," Michael Bergamini, Executive Vice President and Chief Scientific Officer, said in a company news release. "The bioerodible technology in development by pSivida, combined with their proven success in developing sustained delivery devices for the eye, puts them at the forefront of this exciting area."
"Nicox's NO-donating research platform has been validated in both preclinical and human studies for the reduction of IOP," said Nancy Lurker, President & CEO of pSivida. "Combining this novel approach to IOP lowering with our bioerodible, sustained delivery device could offer a unique therapy alternative or adjunct to existing therapies to lower IOP in order to help prevent the development and progression of glaucoma."